Andrew H. Beck, MD PhD

Beth Israel Deaconess Medical Center

Beth Israel Deaconess Medical Center
Phone: (617) 667-4118


abeck2@bidmc.harvard.edu

Andrew H. Beck, MD PhD

Beth Israel Deaconess Medical Center

EDUCATIONAL TITLES

  • Assistant Professor, Pathology, Harvard Medical School
  • Director, Molecular Epidemiology Research Laboratory, Pathology, Beth Israel Deaconess Medical Center

DF/HCC PROGRAM AFFILIATION

Research Abstract

The goal of our laboratory is to develop, apply, and integrate methods in molecular pathology, bio-informatics, and epidemiology for translational cancer genomics research. A major focus of the lab is the study of breast cancer, and we work closely in collaboration with investigators from The Nurses Health Study. In recent years, molecular studies have provided important new insights into our understanding of breast cancer, by demonstrating that breast cancer represents a heterogeneous disease, with distinct disease subtypes driven by distinct sets of molecular abnormalities. Studies are beginning to demonstrate that knowledge of the specific molecular abnormalities driving a patients breast cancer can provide key information for selecting the most appropriate therapy, thereby facilitating a new era of personalized medicine for breast cancer patients. We are interested in all stages of breast carcinogenesis: the lab will use samples from women with benign breast disease to identify molecular and morphologic features associated with increased breast cancer risk; the lab will study samples from women with non-invasive breast cancer (DCIS/LCIS) to identify markers to predict disease recurrence and progression; and the lab will study samples from women with invasive breast cancer to identify clinically significant molecular alterations that impact treatment decisions and are associated with patient survival.

It is hoped that the increased knowledge of cancer molecular pathology generated by the lab will drive both the development of improved cancer prevention strategies for women at increased risk of cancer, and the development of new personalized cancer treatment strategies, tailored specifically to a patients genetic make-up and to genetic changes observed in a patients tumor, leading to enhanced cancer diagnostics and therapeutics, and to improved cure rates for cancer patients.

Publications

Powered by Harvard Catalyst
  • Brown KK, Montaser-Kouhsari L, Beck AH, Toker A. MERIT40 Is an Akt Substrate that Promotes Resolution of DNA Damage Induced by Chemotherapy. Cell Rep 2015; 11:1358-66. PubMed
  • Sangoi AR, Shrestha B, Yang G, Mego O, Beck AH. The Novel Marker GATA3 is Significantly More Sensitive Than Traditional Markers Mammaglobin and GCDFP15 for Identifying Breast Cancer in Surgical and Cytology Specimens of Metastatic and Matched Primary Tumors. Appl Immunohistochem Mol Morphol 2015. PubMed
  • Guo X, Jo VY, Mills A, Zhu S, Lee CH, Espinosa I, Nucci MR, Varma S, Forgo E, Hastie T, Anderson S, Ganjoo K, Beck AH, West R, Fletcher C, van de Rijn M. Clinically relevant molecular subtypes in leiomyosarcoma. Clin Cancer Res 2015. PubMed
  • Zhang X, Eliassen AH, Tamimi RM, Hazra A, Beck AH, Brown M, Collins LC, Rosner B, Hankinson SE. Adult body size and physical activity in relation to risk of breast cancer according to tumor androgen receptor status. Cancer Epidemiol Biomarkers Prev 2015. PubMed
  • Bertrand KA, Scott CG, Tamimi RM, Jensen MR, Pankratz VS, Norman AD, Visscher DW, Couch FJ, Shepherd J, Chen YY, Fan B, Wu FF, Ma L, Beck AH, Cummings SR, Kerlikowske K, Vachon CM. Dense and Non-dense Mammographic Area and Risk of Breast Cancer by Age and Tumor Characteristics. Cancer Epidemiol Biomarkers Prev 2015. PubMed
  • Kaunisto A, Henry WS, Montaser-Kouhsari L, Jaminet SC, Oh EY, Zhao L, Luo HR, Beck AH, Toker A. NFAT1 promotes intratumoral neutrophil infiltration by regulating IL8 expression in breast cancer. Mol Oncol 2015. PubMed
  • Beck AH. Open access to large scale datasets is needed to translate knowledge of cancer heterogeneity into better patient outcomes. PLoS Med. 2015; 12:e1001794. PubMed
  • Wang Y, Tseng JC, Sun Y, Beck AH, Kung AL. Noninvasive imaging of tumor burden and molecular pathways in mouse models of cancer. Cold Spring Harb Protoc 2015; 2015:135-44. PubMed
  • Irshad H, Montaser-Kouhsari L, Waltz G, Bucur O, Nowak JA, Dong F, Knoblauch NW, Beck AH. Crowdsourcing image annotation for nucleus detection and segmentation in computational pathology: evaluating experts, automated methods, and the crowd. Pac Symp Biocomput 2015. PubMed
  • Lochhead P, Chan AT, Nishihara R, Fuchs CS, Beck AH, Giovannucci E, Ogino S. Etiologic field effect: reappraisal of the field effect concept in cancer predisposition and progression. Mod Pathol 2014. PubMed
  • Grabiner BC, Nardi V, Birsoy K, Possemato R, Shen K, Sinha S, Jordan A, Beck AH, Sabatini DM. A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity. 2014. PubMed
  • Elloul S, Kedrin D, Knoblauch NW, Beck AH, Toker A. The adherens junction protein afadin is an AKT substrate that regulates breast cancer cell migration. Mol Cancer Res 2014; 12:464-76. PubMed
  • Chin YR, Yoshida T, Marusyk A, Beck AH, Polyak K, Toker A. Targeting Akt3 signaling in triple-negative breast cancer. Cancer Res 2014; 74:964-73. PubMed
  • Bateman AR, El-Hachem N, Beck AH, Aerts HJ, Haibe-Kains B. Importance of collection in gene set enrichment analysis of drug response in cancer cell lines. Sci Rep 2014; 4:4092. PubMed
  • van de Rijn M, Guo X, Sweeney RT, Beck AH, West RB. Molecular pathological analysis of sarcomas using paraffin-embedded tissue: current limitations and future possibilities. Histopathology 2013; 64:163-70. PubMed
  • Haibe-Kains B, El-Hachem N, Birkbak NJ, Jin AC, Beck AH, Aerts HJ, Quackenbush J. Inconsistency in large pharmacogenomic studies. Nature 2013; 504:389-93. PubMed
  • Bertrand KA, Tamimi RM, Scott CG, Jensen MR, Pankratz VS, Visscher D, Norman A, Couch F, Shepherd J, Fan B, Chen YY, Ma L, Beck AH, Cummings SR, Kerlikowske K, Vachon CM. Mammographic density and risk of breast cancer by age and tumor characteristics. Breast Cancer Res 2014; 15:R104. PubMed
  • Reschke M, Clohessy JG, Seitzer N, Goldstein DP, Breitkopf SB, Schmolze DB, Ala U, Asara JM, Beck AH, Pandolfi PP. Characterization and analysis of the composition and dynamics of the mammalian riboproteome. Cell Rep 2013; 4:1276-87. PubMed
  • Bala R, Pinsky BA, Beck AH, Kong CS, Welton ML, Longacre TA. p16 Is Superior to ProEx C in Identifying High-grade Squamous Intraepithelial Lesions (HSIL) of the Anal Canal. Am J Surg Pathol 2013; 37:659-68. PubMed
  • Beck AH, Knoblauch NW, Hefti MM, Kaplan J, Schnitt SJ, Culhane AC, Schroeder MS, Risch T, Quackenbush J, Haibe-Kains B. Significance analysis of prognostic signatures. PLoS Comput. Biol. 2013; 9:e1002875. PubMed
  • Jeselsohn RM, Werner L, Regan MM, Fatima A, Gilmore L, Collins LC, Beck AH, Bailey ST, He HH, Buchwalter G, Brown M, Iglehart JD, Richardson A, Come SE. Digital quantification of gene expression in sequential breast cancer biopsies reveals activation of an immune response. PLoS ONE 2013; 8:e64225. PubMed
  • Hefti MM, Hu R, Knoblauch NW, Collins LC, Haibe-Kains B, Tamimi RM, Beck AH. Estrogen receptor negative/progesterone receptor positive breast cancer is not a reproducible subtype. Breast Cancer Res 2014; 15:R68. PubMed
  • Ogino S, Beck AH, King EE, Sherman ME, Milner DA, Giovannucci E. Ogino et Al. Respond to "the 21st century epidemiologist". Am J Epidemiol 2012; 176:672-4. PubMed
  • Ogino S, King EE, Beck AH, Sherman ME, Milner DA, Giovannucci E. Interdisciplinary education to integrate pathology and epidemiology: towards molecular and population-level health science. Am J Epidemiol 2012; 176:659-67. PubMed
  • Brunner AL, Beck AH, Edris B, Sweeney RT, Zhu SX, Li R, Montgomery K, Varma S, Gilks T, Guo X, Foley JW, Witten DM, Giacomini CP, Flynn RA, Pollack JR, Tibshirani R, Chang HY, van de Rijn M, West RB. Transcriptional profiling of lncRNAs and novel transcribed regions across a diverse panel of archived human cancers. Genome Biol 2012; 13:R75. PubMed
  • Mills AM, Beck AH, Pourmand N, Le QT, Kong CS. Evaluation of ProExC as a prognostic marker in oropharyngeal squamous cell carcinomas. Am J Surg Pathol 2012; 36:1158-64. PubMed
  • Edris B, Fletcher JA, West RB, van de Rijn M, Beck AH. Comparative gene expression profiling of benign and malignant lesions reveals candidate therapeutic compounds for leiomyosarcoma. Sarcoma 2012; 2012:805614. PubMed
  • Beck AH, Sangoi AR, Leung S, Marinelli RJ, Nielsen TO, van de Vijver MJ, West RB, van de Rijn M, Koller D. Systematic analysis of breast cancer morphology uncovers stromal features associated with survival. Sci Transl Med 2011; 3:108ra113. PubMed
  • Espinosa I, Edris B, Lee CH, Cheng HW, Gilks CB, Wang Y, Montgomery KD, Varma S, Li R, Marinelli RJ, West RB, Nielsen T, Beck AH, van de Rijn M. CSF1 expression in nongynecological leiomyosarcoma is associated with increased tumor angiogenesis. Am J Pathol 2011; 179:2100-7. PubMed
  • Beck AH, Rodriguez-Paris J, Zehnder J, Schrijver I. Evaluation of a gene expression microarray-based assay to determine tissue type of origin on a diverse set of 49 malignancies. Am J Surg Pathol 2011; 35:1030-7. PubMed
  • Wu K, Liu JJ, Adams W, Sonn GA, Mach KE, Pan Y, Beck AH, Jensen KC, Liao JC. Dynamic Real-time Microscopy of the Urinary Tract Using Confocal Laser Endomicroscopy. Urology 2011; 78:225-31. PubMed
  • Younes SF, Beck AH, Ohgami RS, Lossos IS, Levy R, Warnke RA, Natkunam Y. The efficacy of HGAL and LMO2 in the separation of lymphomas derived from small B cells in nodal and extranodal sites, including the bone marrow. Am J Clin Pathol 2011; 135:697-708. PubMed
  • Mills AM, Beck AH, Montgomery KD, Zhu SX, Espinosa I, Lee CH, Subramanian S, Fletcher CD, van de Rijn M, West RB. Expression of subtype-specific group 1 leiomyosarcoma markers in a wide variety of sarcomas by gene expression analysis and immunohistochemistry. Am J Surg Pathol 2011; 35:583-9. PubMed
  • Sangoi AR, Ohgami RS, Pai RK, Beck AH, McKenney JK, Pai RK. PAX8 expression reliably distinguishes pancreatic well-differentiated neuroendocrine tumors from ileal and pulmonary well-differentiated neuroendocrine tumors and pancreatic acinar cell carcinoma. Mod Pathol 2011; 24:412-24. PubMed
  • Pai RK, Beck AH, Mitchem J, Linehan DC, Chang DT, Norton JA, Pai RK. Pattern of lymph node involvement and prognosis in pancreatic adenocarcinoma: direct lymph node invasion has similar survival to node-negative disease. Am J Surg Pathol 2011; 35:228-34. PubMed
  • Wu JM, Beck AH, Pate LL, Witten D, Zhu SX, Montgomery KD, Allison KH, van de Rijn M, West RB. Endogenous versus tumor-specific host response to breast carcinoma: a study of stromal response in synchronous breast primaries and biopsy site changes. Clin Cancer Res 2011; 17:437-46. PubMed
  • Webster JA, Beck AH, Sharma M, Espinosa I, Weigelt B, Schreuder M, Montgomery KD, Jensen KC, van de Rijn M, West R. Variations in stromal signatures in breast and colorectal cancer metastases. J Pathol 2010; 222:158-65. PubMed
  • Younes SF, Beck AH, Lossos IS, Levy R, Warnke RA, Natkunam Y. Immunoarchitectural patterns in follicular lymphoma: efficacy of HGAL and LMO2 in the detection of the interfollicular and diffuse components. Am J Surg Pathol 2010; 34:1266-76. PubMed
  • Sharma M, Beck AH, Webster JA, Espinosa I, Montgomery K, Varma S, van de Rijn M, Jensen KC, West RB. Analysis of stromal signatures in the tumor microenvironment of ductal carcinoma in situ. Breast Cancer Res Treat 2010; 123:397-404. PubMed
  • Sangoi AR, Beck AH, Amin MB, Cheng L, Epstein JI, Hansel DE, Iczkowski KA, Lopez-Beltran A, Oliva E, Paner GP, Reuter VE, Ro JY, Shah RB, Shen SS, Tamboli P, McKenney JK. Interobserver reproducibility in the diagnosis of invasive micropapillary carcinoma of the urinary tract among urologic pathologists. Am J Surg Pathol 2010; 34:1367-76. PubMed
  • Kong CS, Beck AH, Longacre TA. A panel of 3 markers including p16, ProExC, or HPV ISH is optimal for distinguishing between primary endometrial and endocervical adenocarcinomas. Am J Surg Pathol 2010; 34:915-26. PubMed
  • Zhang B, Beck AH, Taube JM, Kohler S, Seo K, Zwerner J, Viakhereva N, Sundram U, Kim YH, Schrijver I, Arber DA, Zehnder JL. Combined use of PCR-based TCRG and TCRB clonality tests on paraffin-embedded skin tissue in the differential diagnosis of mycosis fungoides and inflammatory dermatoses. J Mol Diagn 2010; 12:320-7. PubMed
  • Beck AH, Lee CH, Witten DM, Gleason BC, Edris B, Espinosa I, Zhu S, Li R, Montgomery KD, Marinelli RJ, Tibshirani R, Hastie T, Jablons DM, Rubin BP, Fletcher CD, West RB, van de Rijn M. Discovery of molecular subtypes in leiomyosarcoma through integrative molecular profiling. Oncogene 2010; 29:845-54. PubMed
  • Beck AH, West RB, van de Rijn M. Gene expression profiling for the investigation of soft tissue sarcoma pathogenesis and the identification of diagnostic, prognostic, and predictive biomarkers. Virchows Arch 2010; 456:141-51. PubMed
  • Subramanian S, Thayanithy V, West RB, Lee CH, Beck AH, Zhu S, Downs-Kelly E, Montgomery K, Goldblum JR, Hogendoorn PC, Corless CL, Oliveira AM, Dry SM, Nielsen TO, Rubin BP, Fletcher JA, Fletcher CD, van de Rijn M. Genome-wide transcriptome analyses reveal p53 inactivation mediated loss of miR-34a expression in malignant peripheral nerve sheath tumours. J Pathol 2009; 220:58-70. PubMed
  • Beck AH, Weng Z, Witten DM, Zhu S, Foley JW, Lacroute P, Smith CL, Tibshirani R, van de Rijn M, Sidow A, West RB. 3'-end sequencing for expression quantification (3SEQ) from archival tumor samples. PLoS ONE 2010; 5:e8768. PubMed
  • Pai RK, Beck AH, Norton JA, Longacre TA. Appendiceal mucinous neoplasms: clinicopathologic study of 116 cases with analysis of factors predicting recurrence. Am J Surg Pathol 2010; 33:1425-39. PubMed
  • Natkunam Y, Tedoldi S, Paterson JC, Zhao S, Rodriguez-Justo M, Beck AH, Siebert R, Mason DY, Marafioti T. Characterization of c-Maf transcription factor in normal and neoplastic hematolymphoid tissue and its relevance in plasma cell neoplasia. Am J Clin Pathol 2009; 132:361-71. PubMed
  • Espinosa I, Beck AH, Lee CH, Zhu S, Montgomery KD, Marinelli RJ, Ganjoo KN, Nielsen TO, Gilks CB, West RB, van de Rijn M. Coordinate expression of colony-stimulating factor-1 and colony-stimulating factor-1-related proteins is associated with poor prognosis in gynecological and nongynecological leiomyosarcoma. Am J Pathol 2009; 174:2347-56. PubMed
  • Sangoi AR, Dulai MS, Beck AH, Brat DJ, Vogel H. Distinguishing chordoid meningiomas from their histologic mimics: an immunohistochemical evaluation. Am J Surg Pathol 2009; 33:669-81. PubMed
  • Weinberg OK, Ma L, Seo K, Beck AH, Pai RK, Morales A, Kim Y, Sundram U, Tan D, Horning SJ, Hoppe RT, Natkunam Y, Arber DA. Low stage follicular lymphoma: biologic and clinical characterization according to nodal or extranodal primary origin. Am J Surg Pathol 2009; 33:591-8. PubMed
  • Beck AH, Espinosa I, Edris B, Li R, Montgomery K, Zhu S, Varma S, Marinelli RJ, van de Rijn M, West RB. The macrophage colony-stimulating factor 1 response signature in breast carcinoma. Clin Cancer Res 2009; 15:778-87. PubMed
  • Lee CH, Subramanian S, Beck AH, Espinosa I, Senz J, Zhu SX, Huntsman D, van de Rijn M, Gilks CB. MicroRNA profiling of BRCA1/2 mutation-carrying and non-mutation-carrying high-grade serous carcinomas of ovary. PLoS ONE 2009; 4:e7314. PubMed
  • Beck AH, Espinosa I, Gilks CB, van de Rijn M, West RB. The fibromatosis signature defines a robust stromal response in breast carcinoma. Lab Invest 2008; 88:591-601. PubMed
  • Sabo E, Beck AH, Montgomery EA, Bhattacharya B, Meitner P, Wang JY, Resnick MB. Computerized morphometry as an aid in determining the grade of dysplasia and progression to adenocarcinoma in Barrett's esophagus. Lab Invest 2006; 86:1261-71. PubMed
  • Beck AH. STUDENTJAMA. The Flexner report and the standardization of American medical education. JAMA 2004; 291:2139-40. PubMed
Hide